LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results